查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球癌症生物標記市場：趨勢、預測和競爭分析（~2030 年）
市場調查報告書
商品編碼
1386082

全球癌症生物標記市場：趨勢、預測和競爭分析（~2030 年）

Cancer Biomarkers Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

癌症生物標記趨勢和預測

預計2024年至2030年，全球癌症生物標記市場規模將以14.5%的年複合成長率成長，到2030年將達到約377億美元。這個市場的主要促進因素是癌症治療中個人化醫療的日益導向、人們對癌症早期檢測重要性的認知不斷提高以及政府對癌症研究的支持不斷增加。全球癌症生物標記市場的未來充滿希望，診斷、研發、預測和風險管理市場充滿機會。

癌症生物標記市場洞察

Lucintel 預測，由於乳癌發生率上升以及對該疾病診斷認知的提高，乳癌在預測期內仍將是最大的部分。

在這個市場中，由於癌症盛行率不斷增加以及癌症篩檢計畫的可用性不斷增加，診斷仍然是最大的細分市場。

由於擁有完善的醫療保健系統、不斷上升的癌症發病率以及容易獲得先進醫療技術，北美在預測期內可能仍然是最大的地區。

市場規模/估計：市場規模/估計：以金額預測的癌症生物標記市場規模（10 億美元）

趨勢和預測分析：各細分市場和地區的市場趨勢（2018-2023）和預測（2024-2030）

細分分析：按類型、癌症類型、分析技術、應用和區域等各個細分市場估計癌症生物標記市場規模（十億美元）

區域分析：北美、歐洲、亞太地區和世界其他地區的癌症生物標記市場細分

成長機會：按類型、癌症類型、分析技術、應用和地區對癌症生物標記市場的成長機會進行分析。

策略分析：癌症生物標記市場的併購、新產品開發、競爭形勢等。

基於波特五力模型的產業競爭實力分析

常問問題

Q.1 癌症生物標記的市場規模有多大？

答：到 2030 年，全球癌症生物標記市場預計將達到 377 億美元。

Q.2 癌症生物標記市場的成長預測如何？

答案從2024年到2030年，全球癌症生物標記市場預計將以14.5%的年複合成長率成長。

Q.3 影響癌症生物標記市場成長的關鍵促進因素有哪些？

答：這個市場的主要驅動力是癌症治療中個人化醫療的日益導向、人們對癌症早期檢測重要性的認知不斷提高以及政府對癌症研究的支持不斷增加。

Q4.癌症生物標記市場的主要細分市場有哪些？

答： 癌症生物標記市場的未來充滿希望，診斷、研發、預測和風險管理市場充滿商機。

Q5. 癌症生物標記市場的主要企業有哪些？

答主要的癌症生物標記公司有：

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen NV
  • Bio-Rad Laboratories

Q6. 未來癌症生物標記市場中哪個細分市場會是最大的？

答： Lucintel 預計，由於乳癌發生率不斷上升以及診斷該疾病的意識不斷增強，乳癌在預測期內仍將是其最大的細分市場。

Q7.未來年度哪個地區將成為最大的癌症生物標記市場？

由於擁有完善的醫療保健系統、不斷上升的癌症發病率以及易於獲得先進醫療技術，北美在預測期內仍將是最大的地區。

Q.8 是否可以客製化報告？

答：是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球癌症生物標記市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢與預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症生物標記市場趨勢（2018-2023）與預測（2024-2030）
  • 全球癌症生物標記市場：按類型
    • 蛋白質
    • 遺傳上
    • 其他
  • 全球癌症生物標記市場：按癌症類型
    • 肺
    • 胸部
    • 白血病
    • 黑色素瘤
    • 大腸直腸
    • 攝護腺
    • 甲狀腺
    • 腎
    • 其他
  • 全球癌症生物標記市場：依分析技術分類
    • 體學
    • 影像
    • 免疫檢測
    • 生物資訊學
    • 其他
  • 全球癌症生物標記市場：按應用分類
    • 診斷
    • 研究與開發
    • 預後
    • 危機管理
    • 其他

第4章 市場趨勢與預測分析：按地區（2018-2030）

  • 全球癌症生物標記市場：按地區
  • 北美癌症生物標記市場
  • 歐洲癌症生物標記市場
  • 亞太地區癌症生物標記市場
  • 其他地區的癌症生物標記市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球癌症生物標記市場成長機會
    • 按癌症類型分類的全球癌症生物標記市場成長機會
    • 全球癌症生物標記市場成長機會（按分析技術）
    • 全球癌症生物標記市場成長機會（按應用）
    • 全球癌症生物標記物市場成長機會（按地區）
  • 全球癌症生物標記市場新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球癌症生物標記市場的能力
    • 全球癌症生物標記市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • QIAGEN NV
  • Bio-Rad Laboratories
簡介目錄

Cancer Biomarkers Trends and Forecast

The future of the global cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets. The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.

A more than 150-page report is developed to help in your business decisions.

Cancer Biomarkers by Segment

The study includes a forecast for the global cancer biomarkers by type, cancer, profiling technology, application, and region.

Cancer Biomarkers Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Protein
  • Genetic
  • Others

Cancer Biomarkers Market by Cancer [Shipment Analysis by Value from 2018 to 2030]:

  • Lung
  • Breast
  • Leukemia
  • Melanoma
  • Colorectal
  • Prostate
  • Thyroid
  • Kidney
  • Others

Cancer Biomarkers Market by Profiling Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Omics
  • Imaging
  • Immunoassay
  • Bioinformatics
  • Others

Cancer Biomarkers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnostics
  • R&D
  • Prognostics
  • Risk Management
  • Others

Cancer Biomarkers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Biomarkers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer biomarkers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer biomarkers companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen N.V.
  • Bio-Rad Laboratories

Cancer Biomarkers Market Insights

Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.

Within this market, diagnostic will remain the largest segment due to increasing prevalence of cancer and growing availability of cancer screening programs.

North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.

Features of the Global Cancer Biomarkers Market

Market Size Estimates: Cancer biomarkers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer biomarkers market size by various segments, such as by type, cancer type, profiling technology, application, and region in terms of ($B).

Regional Analysis: Cancer biomarkers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, cancer types, profiling technologies, applications, and regions for the cancer biomarkers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer biomarkers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the cancer biomarkers market size?

Answer: The global cancer biomarkers market is expected to reach an estimated $37.7 billion by 2030.

Q.2 What is the growth forecast for cancer biomarkers market?

Answer: The global cancer biomarkers market is expected to grow with a CAGR of 14.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the cancer biomarkers market?

Answer: The major drivers for this market are increasing inclination towards personalized medicine for cancer treatment, growing awareness towards importance of early detection of cancer, and rising government support for cancer research.

Q4. What are the major segments for cancer biomarkers market?

Answer: The future of the cancer biomarkers market looks promising with opportunities in the diagnostics, R&D, prognostics, and risk management markets.

Q5. Who are the key cancer biomarkers market companies?

Answer: Some of the key cancer biomarkers companies are as follows:

  • F. Hoffmann-La Roche
  • Thermo Fisher Scientific
  • Illumina
  • Qiagen N.V.
  • Bio-Rad Laboratories

Q6. Which cancer biomarkers market segment will be the largest in future?

Answer: Lucintel forecasts that breast cancer will remain the largest segment over the forecast period due to increasing incidence of breast cancer and rising awareness of the diagnosis of this disease.

Q7. In cancer biomarkers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region during the forecast period due to presence of well-established healthcare systems, rising incidence of cancer, and easy accessibility to advanced healthcare technologies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer biomarkers market by type (protein, genetic, and others), cancer type (lung, breast, leukemia, melanoma, colorectal, prostate, thyroid, kidney, and others), profiling technology (omics, imaging, immunoassay, bioinformatics, and others), application (diagnostics, R&D, prognostics, risk management, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Biomarkers Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Biomarkers Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Biomarkers Market by Type
    • 3.3.1: Protein
    • 3.3.2: Genetic
    • 3.3.3: Others
  • 3.4: Global Cancer Biomarkers Market by Cancer Type
    • 3.4.1: Lung
    • 3.4.2: Breast
    • 3.4.3: Leukemia
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal
    • 3.4.6: Prostate
    • 3.4.7: Thyroid
    • 3.4.8: Kidney
    • 3.4.9: Others
  • 3.5: Global Cancer Biomarkers Market by Profiling Technology
    • 3.5.1: Omics
    • 3.5.2: Imaging
    • 3.5.3: Immunoassay
    • 3.5.4: Bioinformatics
    • 3.5.5: Others
  • 3.6: Global Cancer Biomarkers Market by Application
    • 3.6.1: Diagnostics
    • 3.6.2: R&D
    • 3.6.3: Prognostics
    • 3.6.4: Risk Management
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Biomarkers Market by Region
  • 4.2: North American Cancer Biomarkers Market
    • 4.2.2: North American Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.3: European Cancer Biomarkers Market
    • 4.3.1: European Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.3.2: European Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.4: APAC Cancer Biomarkers Market
    • 4.4.1: APAC Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.4.2: APAC Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others
  • 4.5: ROW Cancer Biomarkers Market
    • 4.5.1: ROW Cancer Biomarkers Market by Cancer Type: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Thyroid, Kidney, and Others
    • 4.5.2: ROW Cancer Biomarkers Market by Application: Diagnostics, R&D, Prognostics, Risk Management, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Biomarkers Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Biomarkers Market by Cancer Type
    • 6.1.3: Growth Opportunities for the Global Cancer Biomarkers Market by Profiling Technology
    • 6.1.4: Growth Opportunities for the Global Cancer Biomarkers Market by Application
    • 6.1.5: Growth Opportunities for the Global Cancer Biomarkers Market by Region
  • 6.2: Emerging Trends in the Global Cancer Biomarkers Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Biomarkers Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Biomarkers Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Thermo Fisher Scientific
  • 7.3: Illumina
  • 7.4: QIAGEN N.V.
  • 7.5: Bio-Rad Laboratories